Drugs / Personalized neoantigen tumor vaccine
Personalized neoantigen tumor vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06496373 | Jul 2024 → Jun 2026 overdue | pancreas disorder | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07334574 | Jan 2026 → Jan 2028 expected | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05359354 | Sep 2022 → Sep 2025 | cancer | YueJuan Cheng | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | personalized neoantigen tumor vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06496373 ↗ |
| Known as | XP-004 | “This study primarily aims to assess the safety and tolerability of XP-004 personalized mRNA vaccines encoding tumor neoantigens combined with PD-1 inhibitor as adjuvant therapy...” NCT06496373 ↗ |
| Known as | XP-006 | “XP-006 personalized tumor mRNA vaccine” NCT07334574 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA personalized neoantigen tumor vaccine” NCT05359354 ↗ |